GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (FRA:L7R) » Definitions » Institutional Ownership

Lipidor AB (FRA:L7R) Institutional Ownership : 0.02% (As of Apr. 12, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Lipidor AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lipidor AB's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lipidor AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lipidor AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Lipidor AB Institutional Ownership Historical Data

The historical data trend for Lipidor AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipidor AB Institutional Ownership Chart

Lipidor AB Historical Data

The historical data trend for Lipidor AB can be seen below:

2023-10-31 2024-06-30 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02

Lipidor AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lipidor AB Business Description

Traded in Other Exchanges
Address
c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16
Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines